NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)—update of the NCCN clinical practice guidelines
GD Demetri, RS Benjamin, CD Blanke, JY Blay… - Journal of the National …, 2007 - jnccn.org
The NCCN Soft Tissue Sarcoma Guidelines include a subsection about treatment
recommendations for gastrointestinal stromal tumors (GISTs). The standard of practice …
recommendations for gastrointestinal stromal tumors (GISTs). The standard of practice …
Medication-induced hypophosphatemia: a review
Abstract Hypophosphatemia (serum phosphorus concentration< 2.5 mg/dl, 0.8 mmol/l),
although rare in the general population, is commonly observed in hospitalized patients and …
although rare in the general population, is commonly observed in hospitalized patients and …
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors
GD Demetri, M Von Mehren, CR Antonescu… - Journal of the National …, 2010 - jnccn.org
Background Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal
tumors of the gastrointestinal tract. Neoplastic GIST cells seem to arise from a common …
tumors of the gastrointestinal tract. Neoplastic GIST cells seem to arise from a common …
Dysregulation of bone remodeling by imatinib mesylate
Imatinib mesylate is a rationally designed tyrosine kinase inhibitor that has revolutionized
the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. Although the …
the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. Although the …
Practical management of tyrosine kinase inhibitor-associated side effects in GIST
H Joensuu, JC Trent, P Reichardt - Cancer treatment reviews, 2011 - Elsevier
Patients diagnosed with advanced gastrointestinal stromal tumor (GIST) are currently treated
with oral tyrosine kinase inhibitors (TKIs). Imatinib mesylate is the standard first-line …
with oral tyrosine kinase inhibitors (TKIs). Imatinib mesylate is the standard first-line …
Electrolyte disorders associated with the use of anticancer drugs
The use of anticancer drugs is beneficial for patients with malignancies but is frequently
associated with the occurrence of electrolyte disorders, which can be hazardous and in …
associated with the occurrence of electrolyte disorders, which can be hazardous and in …
Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
E Jabbour, M Deininger, A Hochhaus - Leukemia, 2011 - nature.com
BCR–ABL-targeting tyrosine kinase inhibitors (TKIs) constitute the cornerstone of treatment
for chronic myeloid leukemia. Although these agents are normally safe and effective, they …
for chronic myeloid leukemia. Although these agents are normally safe and effective, they …
Kinase inhibitors: adverse effects related to the endocrine system
MB Lodish - The Journal of Clinical Endocrinology & …, 2013 - academic.oup.com
Context: The use of kinase inhibitors (KIs) in the treatment of cancer has become
increasingly common, and practitioners must be familiar with endocrine-related side effects …
increasingly common, and practitioners must be familiar with endocrine-related side effects …
Hypophosphatemia in cancer patients
S Adhikari, O Mamlouk, H Rondon-Berrios… - Clinical Kidney …, 2021 - academic.oup.com
Dysregulation of phosphorus homeostasis resulting in hypophosphatemia is common in
cancer patients and can result in serious complications and impact outcomes. Several …
cancer patients and can result in serious complications and impact outcomes. Several …
Recognizing endocrinopathies associated with tyrosine kinase inhibitor therapy in children with chronic myelogenous leukemia
J Samis, P Lee, D Zimmerman, RJ Arceci… - Pediatric Blood & …, 2016 - Wiley Online Library
Side effects of tyrosine kinase inhibitor (TKI) treatment vary in children and adults with
chronic myelogenous leukemia (CML). As children have a much longer life expectancy than …
chronic myelogenous leukemia (CML). As children have a much longer life expectancy than …